Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom. / Ulrik, Charlotte Suppli.
In: Ugeskrift for Laeger, Vol. 172, No. 47, 22.11.2010, p. 3260-3.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom
AU - Ulrik, Charlotte Suppli
PY - 2010/11/22
Y1 - 2010/11/22
N2 - The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.
AB - The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.
M3 - Tidsskriftartikel
VL - 172
SP - 3260
EP - 3263
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 47
ER -
ID: 40201733